share_log

4款1类新药首次在中国获批临床,来自阿斯利康、百济神州等

JRJ Finance ·  Aug 17 20:49

根据中国国家药监局药品审评中心官网以及公开资料,本周,有4款1类创新药首次在中国获得临床试验默示许可。它们分别来自绿叶制药、凯思凯迪、百济神州和阿斯利康。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment